6:05 PM
 | 
Feb 21, 2013
 |  BC Extra  |  Company News

EC approves Adasuve

The European Commission approved an MAA for Adasuve Staccato loxapine from Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) to treat mild to moderate agitation in adults with schizophrenia or bipolar disorder. The approval requires that patients receive regular treatment immediately...

Read the full 172 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >